EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis

Sulaiman Mohammed Alnasser iD, Khalid Saad Alharbi, Ali F Almutairy, Sulaiman Mohammed Almutairi, Abdulmalik Mohammed Alolayan

Cells · 2023

DOI: 10.3390/cells12242855 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Sulaiman Mohammed Alnasser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis, Lymphoma, Non-Hodgkin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human body cells are stem cell (SC) derivatives originating from bone marrow. Their special characteristics include their capacity to support the formation and self-repair of the cells. Cancer cells multiply uncontrollably and invade healthy tissues, making stem cell transplants a viable option for cancer patients undergoing high-dose chemotherapy (HDC). When chemotherapy is used at very high doses to eradicate all cancer cells from aggressive tumors, blood-forming cells and leukocytes are either completely or partially destroyed. Autologous stem cell transplantation (ASCT) is necessary for patients in those circumstances. The patients who undergo autologous transplants receive their own stem cells (SCs). The transplanted stem cells first come into contact with the bone marrow and then undergo engraftment, before differentiating into blood cells. ASCT is one of the most significant and innovative strategies for treating diseases. Here we focus on the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, multiple myeloma, and AL amyloidosis, using ASCT. This review provides a comprehensive picture of the effectiveness and the safety of ASCT as a therapeutic approach for these diseases, based on the currently available evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMultiple MyelomaImmunoglobulin Light-chain AmyloidosisLymphoma, Non-HodgkinHumansTransplantation, AutologousStem Cell Transplantation

Stichwörter der Autor:innen

AL amyloidosisHodgkin’s lymphomaautologous stem cell transplantationcancersmultiple myelomanon-Hodgkin’s lymphomaoncology

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Unaizah College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.
  • Unaizah College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.

ORCID-Profile: Sulaiman Mohammed Alnasser

Zitieren

APA

Alnasser, S. M., Alharbi, K. S., Almutairy, A. F., Almutairi, S. M., & Alolayan, A. M. (2023). Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis. Cells. https://doi.org/10.3390/cells12242855

Vancouver

Alnasser SM, Alharbi KS, Almutairy AF, Almutairi SM, Alolayan AM. Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis. Cells. 2023. doi:10.3390/cells12242855

BibTeX
@article{Alnasser2023,
  author = {Alnasser, Sulaiman Mohammed and Alharbi, Khalid Saad and Almutairy, Ali F and Almutairi, Sulaiman Mohammed and Alolayan, Abdulmalik Mohammed},
  title = {Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12242855}
}
Kostenlos starten →